Entera Bio (NASDAQ:ENTX) Shares Down 0.6% – Here’s What Happened

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price traded down 0.6% during mid-day trading on Wednesday . The company traded as low as $1.45 and last traded at $1.54. 610,262 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 2,768,290 shares. The stock had previously closed at $1.55.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ENTX shares. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Entera Bio Trading Down 0.6%

The business’s fifty day moving average is $1.24 and its 200 day moving average is $1.41. The company has a market cap of $75.91 million, a P/E ratio of -5.70 and a beta of 1.56.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. As a group, research analysts expect that Entera Bio Ltd. will post -0.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Superstring Capital Management LP bought a new position in Entera Bio during the fourth quarter worth about $33,000. Citadel Advisors LLC raised its position in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares during the period. HighTower Advisors LLC lifted its stake in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the period. 14.11% of the stock is currently owned by institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.